Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;23(7):635-640.
doi: 10.1016/j.jcyt.2020.12.001. Epub 2020 Dec 11.

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal

Caterina Giovanna Valentini  1 , Patrizia Chiusolo  2 , Maria Bianchi  1 , Elisabetta Metafuni  1 , Nicoletta Orlando  1 , Sabrina Giammarco  1 , Andrea Bacigalupo  2 , Simona Sica  2 , Luciana Teofili  3
Affiliations

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal

Caterina Giovanna Valentini et al. Cytotherapy. 2021 Jul.

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has deeply modified the complex logistical process underlying allogeneic hematopoietic stem cell transplant practices.

Aim: In light of these changes, the authors compared data relative to allogeneic transplants carried out from 2018 at their center before (n = 167) and during the pandemic (n = 45).

Methods: The authors examined patient characteristics, donor and graft types, cell doses and main transplant outcomes. Moreover, the authors evaluated the rise of costs attributable to additional COVID-19-related procedures as well as the risk of adverse events these procedures conveyed to grafts or recipients.

Results: Overall, the number of transplants did not decrease during the pandemic, whereas patients at high relapse risk were prioritized. Transplants were mainly from matched unrelated donors, with a significant decrease in haploidentical related donors. Moreover, the use of bone marrow as a graft for haploidentical transplant was almost abandoned. Cryopreservation was introduced for all related and unrelated apheresis products, with a median storage time of 20 days. Notably, transplant outcomes (engraftment, acute graft-versus-host disease and non-relapse mortality) with cryopreserved products were comparable to those with fresh products.

Conclusions: Considering that the emergency situation may persist for months, cryopreserving allogeneic grafts can offer a lifesaving opportunity for patients whose allogeneic transplant cannot be postponed until after the end of the COVID-19 pandemic.

Keywords: COVID-19 pandemic; allogeneic hematopoietic stem cell transplantation; costs; cryopreservation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Figures

Fig 1
Figure 1
Transplant outcomes in patients receiving fresh (red lines) or cryopreserved (blue lines) products. (A) Cumulative incidence of neutrophil, platelet and reticulocyte engraftment. Reticulocyte engraftment is separately reported in total population and ABO matched/minor mismatched patients. (B) Cumulative incidence of grade II–IV acute GVHD and NRM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_227_0_file.pdf (last accessed on November 16, 2020).
    1. http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_225_0_file.pdf (last accessed on November 16, 2020).
    1. http://www.trapianti.salute.gov.it/imgs/C_17_cntAvvisi_236_0_file.pdf (last accessed on November 16, 2020).
    1. Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S. Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;8:1. - PMC - PubMed
    1. Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020;26(12):2181–2189. doi: 10.1016/j.bbmt.2020.07.021. - DOI - PMC - PubMed